TNF and colitis: TNF-alpha inhibitors are frequently used for the second-line treatments of ICI-associated arthritis and ICI-associated colitis, and RCTs will test whether the early introduction of either infliximab in colitis (NCT05947669) or adalimumab in ICI-associated arthritis (NCT06037811) will shorten the duration of irAE symptoms and reduce steroid requirements.